Outcomes of Living-Donor Liver Transplantation for Cholangiocarcinoma Versus Hepatocellular Carcinoma in the United States
Authors:
- Merve GurakarMGMerve Gurakar
- Ozge Sila OzgurOOOzge Sila Ozgur
- Ayse Eylul DonmezADAyse Eylul Donmez
- Nazli Begum OzturkNONazli Begum Ozturk
- Mehmet M. BilgiliMBMehmet M. Bilgili
- Ximena ParragaXPXimena Parraga
- Marwan AlsaqaMAMarwan Alsaqa
- Eyad AbdulrazzakEAEyad Abdulrazzak
- Shanmukh Sai Pavan LingamsettySLShanmukh Sai Pavan Lingamsetty
- Alan BonderABAlan Bonder
- Ahmet GurakarAGAhmet Gurakar
- Behnam SaberiBSBehnam Saberi
Open Access
- 16 October 2025
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (20) , 7306
Abstract
Objectives: Cholangiocarcinoma (CCA) is a malignancy of the biliary epithelium associated with high mortality. Hepatocellular carcinoma (HCC) is the most common primary liver tumor and has an established indication for liver transplant (LT). Living-donor LT (LDLT) may offer a curative and timely option for selected CCA patients. Methods: The United Network of Organ Sharing/Organ Procurement and Transplantation Network (UNOS/OPTN) data was reviewed from January 2010 to December 2022 for patients who underwent LDLT with HCC or CCA diagnostic codes. Post-LDLT survival for CCA was compared to HCC and non-HCC/CCA patients using Kaplan–Meier analysis. Stepwise multivariate analysis adjusted for recipient age, gender, race, and underlying etiology. Results: LDLT for CCA was most commonly performed in UNOS region 7 (54.9%) and region 2 (12.7%). Among 3993 LDLT recipients, 102 (2.6%) had CCA, 774 (19.4%) had HCC, and 3117 (78%) had neither HCC nor CCA. The 1-, 3- and 5-year post-LDLT survival of patients with CCA were 84.6%, 70.4%, and 62.2% versus 93.1%, 85.2%, and 78.2% for HCC, respectively. Conclusions: CCA accounts for 2.6% of LDLTs compared to 19.4% for HCC in the United States. At 5 years post-LDLT, patients with CCA have significantly lower survival compared to HCC.Keywords
This publication has 42 references indexed in Scilit:
- Transplantation for Hepatocellular CarcinomaSurgical Clinics of North America, 2023
- Liver Transplant for Intrahepatic CholangiocarcinomaSurgical Clinics of North America, 2023
- Liver Transplantation for Intrahepatic Cholangiocarcinoma: Ready for Prime Time?Hepatology, 2021
- Liver Transplantation for Peri-hilar CholangiocarcinomaJournal of Gastrointestinal Surgery, 2020
- Liver transplantation for intrahepatic cholangiocarcinomaLiver Transplantation, 2018
- Current status of liver transplantation for cholangiocarcinomaLiver Transplantation, 2018
- Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessmentHepatology, 2016
- Recurrence Rate and Pattern of Perihilar Cholangiocarcinoma after Curative Intent ResectionJournal of the American College of Surgeons, 2015
- Liver transplantation for cholangiocarcinomaLiver Transplantation, 2015
- Transplantation for hilar cholangiocarcinomaLiver Transplantation, 2004